Literature DB >> 1906938

Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs.

H Mielants1, S Goemaere, M De Vos, K Schelstraete, K Goethals, M Maertens, C Ackerman, E M Veys.   

Abstract

Using the 51Cr-EDTA resorption test, gut permeability was measured in 129 patients with inflammatory joint diseases and in 97 control patients (42 patients with no inflammatory rheumatic disorders taking antiinflammatory medication and 55 healthy controls). Thirty-two patients (30 arthritis and 2 control patients) taking nonsteroidal antiinflammatory drugs (NSAID) as well as corticosteroids were excluded from statistical analysis. The intake of NSAID significantly increased gut permeability in controls but not in the arthritis groups. The same applied to corticosteroid intake. This could be due to the restricted number of arthritis patients who had never taken antiinflammatory drugs or to a disease related increased permeability. There was no statistically significant difference in altered gut permeability between patients taking NSAID and patients taking corticosteroids. Our findings suggest that drug induced alteration of gut permeability may not only be accounted for by an inhibition of mucosal cyclooxygenase activity, but that other enzymatic pathways in the arachidonic cascade might be implicated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906938

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Increased intestinal permeability in ankylosing spondylitis.

Authors:  H Mielants; E M Veys; M De Vos; C Cuvelier
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

2.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 3.  Nonsteroidal anti-inflammatory drugs. Differential use in older patients.

Authors:  L Girgis; P Brooks
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

4.  Antiinflammatory drug-induced small intestinal permeability: the rat is a suitable model.

Authors:  N M Davies; M R Wright; F Jamali
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 5.  Intestinal permeability to [51Cr]EDTA in infectious diarrhea.

Authors:  M J Zuckerman; M T Watts; B D Bhatt; H Ho
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

Review 6.  Non-invasive investigation in patients with inflammatory joint disease.

Authors:  Elisabetta Dal Pont; Renata D'Incà; Antonino Caruso; Giacomo-Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

7.  Mitochondrial N-formyl methionine peptides associate with disease activity as well as contribute to neutrophil activation in patients with rheumatoid arthritis.

Authors:  Bhargavi Duvvuri; Al Anoud Baddour; Kevin D Deane; Marie L Feser; J Lee Nelson; M Kristen Demoruelle; Christian Lood
Journal:  J Autoimmun       Date:  2021-03-10       Impact factor: 7.094

Review 8.  The gut-joint axis in rheumatoid arthritis.

Authors:  Mario M Zaiss; Hsin-Jung Joyce Wu; Daniele Mauro; Georg Schett; Francesco Ciccia
Journal:  Nat Rev Rheumatol       Date:  2021-03-05       Impact factor: 32.286

9.  Investigation of infectious agents associated with arthritis by reverse transcription PCR of bacterial rRNA.

Authors:  Charles J Cox; Karen E Kempsell; J S Hill Gaston
Journal:  Arthritis Res Ther       Date:  2002-10-11       Impact factor: 5.156

10.  Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease.

Authors:  Diana E Matei; Madhvi Menon; Dagmar G Alber; Andrew M Smith; Bahman Nedjat-Shokouhi; Alessio Fasano; Laura Magill; Amanda Duhlin; Samuel Bitoun; Aude Gleizes; Salima Hacein-Bey-Abina; Jessica J Manson; Elizabeth C Rosser; Nigel Klein; Paul A Blair; Claudia Mauri
Journal:  Med (N Y)       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.